Yahong Pharmaceutical (688176.SH): The marketing application for APL-1702 (Hexyl Hydrochloride Ointment Photodynamic Therapy System) was accepted
Gelonghui, May 12 | Yahong Pharmaceutical (688176.SH) announced that the company recently received the “Notice of Acceptance” approved and issued by the National Drug Administration (NMPA). The company's product APL-1702 (generic name: aminonovalerate ointment photodynamic therapy system) is intended to treat high-grade cervical squamous intraepithelial lesion (HSIL) patients aged 18 and above to eliminate cancer in situ (HSIL) Accepted. APL-17
Yahong Pharmaceutical (688176.SH): A total of 0.6266% of shares have been repurchased
Gelonghui, May 6, 丨 Yahong Pharmaceutical (688176.SH) announced that as of April 30, 2024, the company had repurchased a total of 3,571,534 shares, accounting for 0.6266% of the company's total share capital. The highest price of the repurchase transaction was RMB 6.73 yuan/share, the lowest price was RMB 5.33 yuan/share, and the total capital paid was RMB 22.9833 million (excluding transaction fees such as stamp duty and transaction fees).
Yahong Pharmaceutical (688176.SH)'s revenue in the first quarter increased 126% month-on-month
On April 29, Yahong Pharmaceutical (stock code: 688176.SH) released its report for the first quarter of 2024. The company achieved revenue of 243.195 million yuan in the first quarter, an increase of 126.08% over the previous quarter. This was mainly due to the company's sales of commercial products, pezopanib tablets (trade name: Dipite) and neratinib maleate tablets (trade name: OUBI) during the reporting period. Depat and Oubi went on sale in October and December 2023 respectively, and product sales increased in the first quarter of this year.
Yahong Pharmaceutical (688176.SH) announced 2023 annual results, all core products are under development, and net loss increased to 400 million yuan
Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved operating income of 13 during the reporting period...
Yahong Pharmaceutical: Significant revenue growth in 2023 Core product APL-1702? New drug marketing applications are expected to be accepted in Q2
Gelonghui, April 17 | Yahong Pharmaceutical released its annual report. In 2023, the company achieved operating income of 13.7533 million yuan, an increase of 137.272 million yuan over the same period last year. The revenue growth was mainly due to sales revenue and license fee revenue generated by prazopanib tablets and neratinib maleate tablets in Q4 of 2023. In addition, the company's core products have made many advances. For example, APL-1702 is actively preparing to submit a new drug marketing application, and Q2 is expected to be accepted; APL-1706's new drug marketing application has been accepted; and APL-1202 and PD-1's phase II clinical trial analysis has been positive
Yahong Pharmaceutical (688176.SH): APL-1706 has reached the main research endpoint of phase III clinical trials. The application for marketing has been accepted
Yahong Pharmaceutical (688176.SH) announced that the company APL-1706 is a multi-center for bladder cancer diagnosis...
Yahong Pharmaceutical (688176.SH): Release of APL-1702 international multi-center phase III clinical trial data for the treatment of high-grade squamous intraepithelial lesion of the cervix
Gelonghui, March 18 | Yahong Pharmaceutical (688176.SH) announced that recently, Jiangsu Yahong Pharmaceutical Technology Co., Ltd. product APL1702 for treating high-grade cervical squamous intraepithelial lesion (HSIL) prospective, randomized, double-blind, placebo-controlled international multi-center phase III clinical trial results were selected for the 2024 European Genital Infection and Oncology Research Organization Conference (EUROGIN) and 2024 American Gynecological Oncology Society Annual Meeting (SGO), and
While Institutions Invested in Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Benefited From Last Week's 10% Gain, Retail Investors Stood to Gain the Most
Key Insights The considerable ownership by retail investors in Jiangsu Yahong Meditech indicates that they collectively have a greater say in management and business strategy 50% of the business is
Yahong Pharmaceutical (688176.SH): A total cost of 8.142,100 yuan to buy back 0.2325% of the shares
Gelonghui, Feb. 29丨Yahong Pharmaceutical (688176.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,325,215 shares, accounting for 0.2325% of the company's total share capital. The highest price of the repurchase transaction was RMB 6.66 yuan/share, the lowest price was RMB 5.33 yuan/share, and the total amount of capital paid was RMB 8.1421 million.
Yahong Pharmaceutical (688176.SH) Performance Report: Net loss of 400 million yuan in 2023
Gelonghui, Feb. 23 | Yahong Pharmaceutical (688176.SH) announced its 2023 annual performance report. During the reporting period, the company achieved operating income of 13.7533 million yuan; net profit attributable to owners of the parent company was -400 million yuan, with net loss increasing year-on-year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was -432.5 million yuan, with net loss increasing year-on-year after deduction.
Yahong Pharmaceutical will announce the APL-1702 international multi-center phase III clinical trial data of its non-surgical cervical HSIL product at SGO in 2024
SHANGHAI, Feb. 23, 2024/PRNewswire/ -- Yahong Pharmaceutical (stock code: 688176.SH), a global innovative pharmaceutical company focusing on urogenital tumors, recently announced that the results of the APL-1702 international multi-center phase III clinical trial of its non-surgical treatment of cervical HSIL product were selected for the American Society of Gynecologic Oncology (SGO) Late Breaking Oral Presentation (SGO) held on March 16-18, 2024, and will release clinical trial data in the form of an oral report. Oral Report: APL-170
Yahong Pharmaceutical (688176.SH): Initial repurchase of 182,800 shares
Gelonghui, February 8, 丨 Yahong Pharmaceutical (688176.SH) announced that on February 8, 2024, the company repurchased 182,800 shares for the first time through the Shanghai Stock Exchange trading system, accounting for 0.0321% of the company's total share capital. The highest price of the repurchase transaction was RMB 5.52 per share, the lowest price was RMB 5.33 yuan/share, and the total capital paid was RMB 999,176.00 (excluding transaction fees such as stamp duty and transaction fees).
Yahong Pharmaceutical (688176.SH): Plans to spend 50 million yuan to 100 million yuan to buy back shares
Gelonghui, Feb. 6 | Yahong Pharmaceutical (688176.SH) announced that the company plans to repurchase some of the company's publicly issued RMB common stock (A shares) shares through centralized bidding transactions through the Shanghai Stock Exchange trading system for equity incentives and/or employee stock ownership plans. If the company fails to use up the repurchased shares within 3 years after the share repurchase implementation results and share change announcement, the unused repurchased shares will be cancelled. If the country adjusts the relevant policies, then this repurchase plan will be implemented in accordance with the adjusted policy. The total capital for the repurchase of shares is not less than RMB 50 million (incl.
Dragon Tiger List | Cambridge Technology was sold for 155 million yuan, and 4 institutions fled Yahong Pharmaceutical for more than 69 million yuan
The top three net sales in today's Dragon Tiger list are Cambridge Technology, Nongshang Environmental, and Yahong Pharmaceutical
Yahong Pharmaceutical (688176.SH): Discontinuing the combined use of APL-1202 and chemotherapy perfusion in the further development of related indications
Gelonghui, Feb. 4: Yahong Pharmaceutical (688176.SH) announced that recently, a key randomized, double-blind, controlled, multi-center clinical trial of the company's product APL1202 combined with chemotherapy infusion to treat medium- and high-risk non-muscle-invasive bladder cancer (NMIBC) recurrent with chemotherapy perfusion has been completed. Statistical analysis results showed that although showing a certain trend of efficacy among some patients, this study did not reach the main study end point, and the company decided to stop further development of APL-1202 in combination with chemotherapy infusion for this indication. As of December 31, 2023, APL-
Yahong Pharmaceutical (688176.SH): Chairman and some directors and senior management plan to increase the company's shares by 4 million yuan to 8 million yuan
Gelonghui, Feb. 4: Yahong Pharmaceutical (688176.SH) announced that the controlling shareholder, actual controller, chairman and general manager, Mr. Yang Mingyuan, director, board secretary and financial director, plans to increase the company's shares within 6 months from February 5, 2024 through methods permitted by the Shanghai Stock Exchange system. The total increase amount is not less than RMB 4 million and no more than RMB 8 million to maintain the company's stock price stability and establish a good market image.
Yahong Pharmaceutical (688176.SH): The international multi-center phase III clinical trial of APL-1702 for the treatment of high-grade squamous intraepithelial lesions of the cervix has reached the main research end
Ge Longhui, January 31 | Yahong Pharmaceutical (688176.SH) recently said during a survey receiving institutional investors that the international multi-center phase III clinical trial of APL-1702 to treat high-grade squamous intraepithelial lesions of the cervix has reached the main research end point and will disclose data from this clinical trial at the 2024 European Association for Research on Genital Tract Infections and Oncology (EUROGIN) conference. The company will actively communicate with the regulatory authorities to submit the drug's new drug marketing application. Regarding the NDA situation, the company will strictly abide by the “Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules”, etc.
Yahong Pharmaceutical (688176.SH): APL-1202 is currently focusing on three clinical trials
Ge Longhui, January 31 | Yahong Pharmaceutical (688176.SH) recently said during a survey of institutional investors that APL-1202 is currently focusing on three clinical trials. The phase I/II clinical trial of APL-1202 oral combined with tirelizumab as a new adjuvant treatment for muscle-invasive bladder cancer (MIBC) completed the phase II clinical trial in September 2023 and achieved positive results, and the mid-clinical trial analysis results will be disclosed at the 2024 American Society of Clinical Oncology Urogenital Oncology Branch (ASCO-GU) annual meeting ; APL-1202 and
Yahong Pharmaceutical announced APL-1706 phase III clinical trial and real-world research data for bladder cancer diagnosis and management drug in 2024 ASCO-GU
SHANGHAI, January 29, 2024/PRNewswire/ -- Yahong Pharmaceutical (stock code: 688176.SH), a global innovative pharmaceutical company focusing on urogenital tumors, recently announced that the company announced phase III clinical trial data and real-world research data for the diagnosis and management of bladder cancer in the form of a poster (abstract number: 593) at the 2024 American Society of Clinical Oncology Symposium on Urogenital Oncology (ASCO GU). A total of 158 patients were included in the randomized controlled study
In 2024 ASCO-GU, Yahong Pharmaceutical first published the analysis data of APL-1202 and the PD-1 inhibitor tirelizumab in combination with the new adjuvant treatment of muscle-invasive bladder cancer phase II clinical trial
SHANGHAI, January 29, 2024/PRNewswire/ -- Yahong Pharmaceutical (stock code: 688176.SH), a global innovative pharmaceutical company focusing on urogenital tumors, announced that it first released APL-1202 oral combined with tiralizumab in the form of a quick oral report summary (abstract number: 632) at the 2024 American Society of Clinical Oncology Symposium on Urogenital Tumors (ASCO GU). The trial has recently completed enrolling all participants. Phase II is coming
No Data